Literature DB >> 1373189

Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.

K L Preston1, I A Liebson, G E Bigelow.   

Abstract

The stimulus properties of four opioid agonist-antagonists were assessed in postaddict volunteers trained in a two-choice drug discrimination procedure to discriminate between the effects of i.m. saline and hydromorphone (3 mg/70 kg). Behavioral, subjective and physiological measures were concurrently collected. After training, generalization curves were determined for hydromorphone, pentazocine, butorphanol, nalbuphine and buprenorphine. In generalization testing, hydromorphone produced dose-related increases in hydromorphone-appropriate responses and in characteristic opioid agonist-like subjective effects measures. In general, each of the study drugs produced a profile of subjective and physiological effects similar to that reported in other human studies. These subjective indices showed the study drugs to be heterogeneous. However, in this two-choice drug discrimination procedure, they were discriminated as homogeneous (i.e., all were discriminated as hydromorphone-like). The present study also found that all test drugs were subjectively identified as being opiates, and all were subjectively rated as similar to the hydromorphone training condition. A previous three-choice discrimination was sensitive to the heterogeneity among these drugs on both the discrimination measures and subjective ratings of similarity to the hydromorphone training condition. Thus, the specific procedures of drug discrimination studies may have an effect on some subjective indices, although this interaction is not apparent for the majority of subjective effect measures. Also, the characterization of opioids in drug discrimination testing appears to depend upon the specific training subjects receive; this is most clear with discrimination measures, and to a more limited extent, with subjective measures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373189

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

2.  Progesterone effects on the discriminative stimulus, subjective and performance effects of triazolam in healthy, premenopausal women.

Authors:  Shanna Babalonis; Joshua A Lile; Catherine A Martin; Thomas H Kelly
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 3.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Drug discrimination by humans compared to nonhumans: current status and future directions.

Authors:  J B Kamien; W K Bickel; J R Hughes; S T Higgins; B J Smith
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 5.  Human drug discrimination: A primer and methodological review.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; Craig R Rush
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

6.  Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.

Authors:  S L Walsh; A E Chausmer; E C Strain; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2007-10-02       Impact factor: 4.530

7.  Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Thomas H Kelly; David J Pinsky; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2008-11-19       Impact factor: 4.530

8.  Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users.

Authors:  S Mogali; P Askalsky; G Madera; J D Jones; S D Comer
Journal:  Pharmacol Biochem Behav       Date:  2021-07-21       Impact factor: 3.697

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.